R

Rhythm Pharmaceuticals
D

RYTM

56.070
USD
0.55
(0.99%)
مغلق
حجم التداول
0
الربح لكل سهم
-4
العائد الربحي
-
P/E
-13
حجم السوق
3,445,897,859
أصول ذات صلة
    A
    ARWR
    -0.020
    (-0.10%)
    19.450 USD
    C
    CRBP
    -0.370
    (-2.78%)
    12.960 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    P
    PRQR
    0.06500
    (2.52%)
    2.64500 USD
    Q
    QURE
    1.550
    (10.00%)
    17.050 USD
    R
    RARE
    0.770
    (1.77%)
    44.190 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    V
    VYGR
    0.06000
    (1.05%)
    5.76000 USD
    المزيد
الأخبار

العنوان: Rhythm Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.